190321-63-2

Upstream product

• 179110-50-0 diethyl 2-((6-chloro-1,3-benzodioxol-5-yl) methyl)-3-oxo 1,4-butanedioate 
• 179110-48-6 (E)-3-(6-Chloro-benzo[1,3]dioxol-5-yl)-acrylic acid ethyl ester 
• 15952-61-1 6-chloropiperonal 
• 6165-69-1 Thien-3-ylboronic acid 
• 190321-60-9 5-bromo-4-(6-chloro-benzo[1,3]dioxol-5-ylmethyl)-2-cyclohexylmethyl-2H-pyrazole-3-carboxylic acid ethyl ester 
• 190321-58-5 ethyl 4-((6-chloro 1,3-benzodioxol-5-yl) methyl) 1-(2-cyanoethyl) 5-hydroxy 1H-pyrazole 3-carboxylate 
• 190321-59-6 ethyl 4-((6-chloro 1,3-benzodioxol-5-yl) methyl) 1-(2-cyanoethyl) 5-bromo 1H-pyrazole 3-carboxylate 
• 179110-49-7 ethyl 6-chloro-1,3-benzodioxol-5-propanoate 

Relevant academic research and scientific papers

Potent nonpeptide endothelin antagonists: Synthesis and structure-activity relationships of pyrazole-5-carboxylic acids

We have previously reported the identification of pyrazole-5-carboxylic acids as a new class of endothelin antagonists from low affinity pyrazol-5-ol ligands, which were obtained by random screening assays.1 We describe herein the synthesis and the structure-activity relationships (SARs) of these pyrazole-5-carboxylic acids with potent ET(A) selective, mixed ET(A)/ET(B) or moderately ET(B) selective antagonist activities. (C) 2000 Elsevier Science Ltd.

Acid pyrazole derivatives, preparation method therefor, use thereof as drugs, novel use therefor, and pharmaceutical compositions containing such derivatives

The subject of the invention is the products of formula (I): in which one of A and B represents a nitrogen atom and the other one of A and B represents a methine radical, such that: A represents either nitrogen substituted in particular by alkyl,